請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/102129完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 郭靜穎 | zh_TW |
| dc.contributor.advisor | Ching-Ying Kuo | en |
| dc.contributor.author | 湯旻樺 | zh_TW |
| dc.contributor.author | Min-Hua Tang | en |
| dc.date.accessioned | 2026-03-13T16:39:59Z | - |
| dc.date.available | 2026-03-14 | - |
| dc.date.copyright | 2026-03-13 | - |
| dc.date.issued | 2026 | - |
| dc.date.submitted | 2026-02-03 | - |
| dc.identifier.citation | 1. Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2024. 74(3): p. 229–263.
2. Fu, M., et al., Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050. The Breast, 2025. 79: p. 103835. 3. 衛生福利部國民健康署, 111年癌症登記資料. 2024. 4. 衛生福利部, 113 年死因統計結果分析. 2025. 5. Jenkins, S., et al., Rare Breast Cancer Subtypes. Current Oncology Reports, 2021. 23(5): p. 54. 6. Nathan, M.R. and P. Schmid, A Review of Fulvestrant in Breast Cancer. Oncology and Therapy, 2017. 5(1): p. 17–29. 7. Carpenter, R. and W.R. Miller, Role of aromatase inhibitors in breast cancer. British Journal of Cancer, 2005. 93(1): p. S1–S5. 8. Wang, X., et al., Recent progress of CDK4/6 inhibitors’ current practice in breast cancer. Cancer Gene Therapy, 2024. 31(9): p. 1283–1291. 9. Swain, S.M., M. Shastry, and E. Hamilton, Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery, 2023. 22(2): p. 101–126. 10. Swain, S.M., et al., Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2015. 372(8): p. 724–734. 11. Schlam, I. and S.M. Swain, HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. npj Breast Cancer, 2021. 7(1): p. 56. 12. Li, Q., et al., HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial. Nature Communications, 2024. 15(1): p. 5158. 13. Thomas, A., B.A. Teicher, and R. Hassan, Antibody–drug conjugates for cancer therapy. The Lancet Oncology, 2016. 17(6): p. e254–e262. 14. Comen, E.A. and M. Robson, Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. The Cancer Journal, 2010. 16(1). 15. Li, H., et al., Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Cancer Cell International, 2025. 25(1): p. 139. 16. Jabbarzadeh Kaboli, P., et al., Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res, 2022. 12(4): p. 1671–1685. 17. Wang, R., et al., The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer, 2019. 19(1): p. 1091. 18. Chen, W., et al., Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precision Oncology, 2018. 2(1): p. 4. 19. Fares, J., et al., Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduction and Targeted Therapy, 2020. 5(1): p. 28. 20. Achrol, A.S., et al., Brain metastases. Nature Reviews Disease Primers, 2019. 5(1): p. 5. 21. Niwińska, A., M. Murawska, and K. Pogoda, Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Annals of Oncology, 2010. 21(5): p. 942–948. 22. Aversa, C., et al., Metastatic breast cancer subtypes and central nervous system metastases. The Breast, 2014. 23(5): p. 623–628. 23. Kuksis, M., et al., The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro-Oncology, 2021. 23(6): p. 894–904. 24. Blanchette, M. and R. Daneman, Formation and maintenance of the BBB. Mechanisms of Development, 2015. 138: p. 8–16. 25. Choi, J.J., et al., Molecules of Various Pharmacologically-Relevant Sizes Can Cross the Ultrasound-Induced Blood-Brain Barrier Opening in vivo. Ultrasound in Medicine & Biology, 2010. 36(1): p. 58–67. 26. Stemmler, H.-J., et al., Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anti-Cancer Drugs, 2007. 18(1). 27. Pestalozzi, B.C., et al., CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). The Lancet Oncology, 2013. 14(3): p. 244–248. 28. Vogelbaum, M.A., et al., Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Journal of Clinical Oncology, 2021. 40(5): p. 492–516. 29. Brown, P.D., et al., Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology, 2017. 18(8): p. 1049–1060. 30. Beloribi-Djefaflia, S., S. Vasseur, and F. Guillaumond, Lipid metabolic reprogramming in cancer cells. Oncogenesis, 2016. 5(1): p. e189–e189. 31. Snaebjornsson, M.T., S. Janaki-Raman, and A. Schulze, Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. Cell Metabolism, 2020. 31(1): p. 62–76. 32. Pan, J., et al., CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3β/β-catenin pathway. Journal of Experimental & Clinical Cancer Research, 2019. 38(1): p. 52. 33. Ladanyi, A., et al., Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene, 2018. 37(17): p. 2285–2301. 34. Zaoui, M., et al., Breast-Associated Adipocytes Secretome Induce Fatty Acid Uptake and Invasiveness in Breast Cancer Cells via CD36 Independently of Body Mass Index, Menopausal Status and Mammary Density. Cancers (Basel), 2019. 11(12). 35. Gaffar, S. and A.S. Aathirah, Fatty-Acid-Binding Proteins: From Lipid Transporters to Disease Biomarkers. Biomolecules, 2023. 13(12). 36. Furuhashi, M., et al., Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clin Med Insights Cardiol, 2014. 8(Suppl 3): p. 23–33. 37. Garin-Shkolnik, T., et al., FABP4 Attenuates PPARγ and Adipogenesis and Is Inversely Correlated With PPARγ in Adipose Tissues. Diabetes, 2014. 63(3): p. 900–911. 38. Gharpure, K.M., et al., FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 2018. 9(1): p. 2923. 39. Apaya, M.K., et al., Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer. Journal of Experimental & Clinical Cancer Research, 2019. 38(1): p. 187. 40. Apaya, M.K., et al. Deregulating the CYP2C19/Epoxy-Eicosatrienoic Acid-Associated FABP4/FABP5 Signaling Network as a Therapeutic Approach for Metastatic Triple-Negative Breast Cancer. Cancers, 2020. 12, DOI: 10.3390/cancers12010199. 41. Zhang, Y., et al., High expression of FABP4 and FABP6 in patients with colorectal cancer. World Journal of Surgical Oncology, 2019. 17(1): p. 171. 42. Chen, Z., et al., Screening and discrimination of optimal prognostic genes for pancreatic cancer based on a prognostic prediction model. G3 (Bethesda), 2021. 11(11). 43. Pai, F.-C., et al. Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells. Cells, 2021. 10, DOI: 10.3390/cells10102782. 44. Go, G.W. and A. Mani, Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med, 2012. 85(1): p. 19–28. 45. Guo, D., et al., An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov, 2011. 1(5): p. 442–56. 46. Palmieri, F., The mitochondrial transporter family SLC25: Identification, properties and physiopathology. Molecular Aspects of Medicine, 2013. 34(2): p. 465–484. 47. Akram, M., Citric Acid Cycle and Role of its Intermediates in Metabolism. Cell Biochemistry and Biophysics, 2014. 68(3): p. 475–478. 48. Ferraro, G.B., et al., Fatty acid synthesis is required for breast cancer brain metastasis. Nature Cancer, 2021. 2(4): p. 414–428. 49. Wen, J., et al., ACLY facilitates colon cancer cell metastasis by CTNNB1. Journal of Experimental & Clinical Cancer Research, 2019. 38(1): p. 401. 50. Wang, M.D., et al., Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. Hepatology, 2016. 63(4): p. 1272–86. 51. Jeon, S.-M., N.S. Chandel, and N. Hay, AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 2012. 485(7400): p. 661–665. 52. Rios Garcia, M., et al., Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence. Cell Metab, 2017. 26(6): p. 842–855.e5. 53. Jiang, L., et al., Up-regulated FASN expression promotes transcoelomic metastasis of ovarian cancer cell through epithelial-mesenchymal transition. Int J Mol Sci, 2014. 15(7): p. 11539–54. 54. Wang, J., et al., The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. Front Oncol, 2022. 12: p. 899987. 55. Serhan, H.A., et al., Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion. npj Breast Cancer, 2024. 10(1): p. 43. 56. Juarez, D. and D.A. Fruman, Targeting the Mevalonate Pathway in Cancer. Trends in Cancer, 2021. 7(6): p. 525–540. 57. Guerra, B., et al., The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Frontiers in Oncology, 2021. Volume 11 - 2021. 58. Li, J., et al., Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene, 2016. 35(50): p. 6378–6388. 59. Antalis, C.J., et al., Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clinical & Experimental Metastasis, 2011. 28(8): p. 733–741. 60. Wang, I.H., et al., Mevalonate Pathway Enzyme HMGCS1 Contributes to Gastric Cancer Progression. Cancers (Basel), 2020. 12(5). 61. Qiu, Z., et al., HMGCR positively regulated the growth and migration of glioblastoma cells. Gene, 2016. 576(1, Part 1): p. 22–27. 62. Zhong, C., et al., HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumour Biol, 2014. 35(5): p. 4123–9. 63. Chushi, L., et al., HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene, 2016. 587(1): p. 42–7. 64. Han, G.-S. and G.M. Carman, Phospholipid Synthesis in Yeast, in Encyclopedia of Biological Chemistry, W.J. Lennarz and M.D. Lane, Editors. 2004, Elsevier: New York. p. 321–325. 65. Blunsom, N.J. and S. Cockcroft, CDP-Diacylglycerol Synthases (CDS): Gateway to Phosphatidylinositol and Cardiolipin Synthesis. Front Cell Dev Biol, 2020. 8: p. 63. 66. Obaseki, E., et al., Lipid droplets and fatty acid-induced lipotoxicity: in a nutshell. FEBS Lett, 2024. 598(10): p. 1207–1214. 67. Duelund, L., et al., Composition, structure and properties of POPC–triolein mixtures. Evidence of triglyceride domains in phospholipid bilayers. Biochimica et Biophysica Acta (BBA) - Biomembranes, 2013. 1828(8): p. 1909–1917. 68. Choudhary, V., et al., A conserved family of proteins facilitates nascent lipid droplet budding from the ER. J Cell Biol, 2015. 211(2): p. 261–71. 69. Wang, H., et al., Seipin is required for converting nascent to mature lipid droplets. Elife, 2016. 5. 70. Griseti, E., et al., Molecular mechanisms of perilipin protein function in lipid droplet metabolism. FEBS Lett, 2024. 598(10): p. 1170–1198. 71. Grabner, G.F., et al., Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nature Metabolism, 2021. 3(11): p. 1445–1465. 72. Fu, H., et al., NPR1 Promotes Lipid Droplet Lipolysis to Enhance Mitochondrial Oxidative Phosphorylation and Fuel Gastric Cancer Metastasis. Advanced Science, 2025. n/a(n/a): p. e03233. 73. Zechner, R., F. Madeo, and D. Kratky, Cytosolic lipolysis and lipophagy: two sides of the same coin. Nature Reviews Molecular Cell Biology, 2017. 18(11): p. 671–684. 74. Kaushik, S. and A.M. Cuervo, Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nature Cell Biology, 2015. 17(6): p. 759–770. 75. Console, L., et al., The Link Between the Mitochondrial Fatty Acid Oxidation Derangement and Kidney Injury. Front Physiol, 2020. 11: p. 794. 76. Adeva-Andany, M.M., et al., Mitochondrial β-oxidation of saturated fatty acids in humans. Mitochondrion, 2019. 46: p. 73–90. 77. Janssen, U. and W. Stoffel, Disruption of Mitochondrial β-Oxidation of Unsaturated Fatty Acids in the 3,2-trans-Enoyl-CoA Isomerase-deficient Mouse*. Journal of Biological Chemistry, 2002. 277(22): p. 19579–19584. 78. Schulz, H. and W.-H. Kunau, Beta-oxidation of unsaturated fatty acids: a revised pathway. Trends in Biochemical Sciences, 1987. 12: p. 403–406. 79. Wright, H.J., et al., CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proceedings of the National Academy of Sciences, 2017. 114(32): p. E6556–E6565. 80. Park, Jun H., et al., Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Reports, 2016. 14(9): p. 2154–2165. 81. Wang, Y.-n., et al., CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. Oncogene, 2018. 37(46): p. 6025–6040. 82. Tang, M., et al., CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma. Cell Death & Disease, 2022. 13(4): p. 331. 83. Shao, H., et al., Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget, 2016. 7(4): p. 3832–46. 84. Siegel, M.B., et al., Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. The Journal of Clinical Investigation, 2018. 128(4): p. 1371–1383. 85. Cosgrove, N., et al., Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nature Communications, 2022. 13(1): p. 514. 86. Subramanian, A., et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences, 2005. 102(43): p. 15545–15550. 87. Mootha, V.K., et al., PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics, 2003. 34(3): p. 267–273. 88. Zhang, B., et al., Adhesion to the Brain Endothelium Selects Breast Cancer Cells with Brain Metastasis Potential. International Journal of Molecular Sciences, 2023. 24(8): p. 7087. 89. Chhichholiya, Y., et al., Brain metastasis in breast cancer: focus on genes and signaling pathways involved, blood–brain barrier and treatment strategies. Clinical and Translational Oncology, 2023. 25(5): p. 1218–1241. 90. Wang, Y., et al., Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies. British Journal of Cancer, 2021. 125(8): p. 1056–1067. 91. Valiente, M., et al., Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis. Cell, 2014. 156(5): p. 1002–1016. 92. Zhang, X., et al., Decoding the mechanisms underlying breast cancer brain metastasis: paving the way for precision therapeutics. Biomark Res, 2025. 13(1): p. 144. 93. Xiao, W., et al., SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF. Molecular Therapy - Oncolytics, 2020. 17: p. 118–129. 94. Godinho-Pereira, J., et al., Behind Brain Metastases Formation: Cellular and Molecular Alterations and Blood–Brain Barrier Disruption. International Journal of Molecular Sciences, 2021. 22(13): p. 7057. 95. Martin, A.M., et al., Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncology, 2017. 3(8): p. 1069–1077. 96. Koundouros, N. and G. Poulogiannis, Reprogramming of fatty acid metabolism in cancer. British Journal of Cancer, 2020. 122(1): p. 4–22. 97. Li, M., et al., Fatty acid oxidation: driver of lymph node metastasis. Cancer Cell International, 2021. 21(1): p. 339. 98. Khanna, C. and K. Hunter, Modeling metastasis in vivo. Carcinogenesis, 2005. 26(3): p. 513–523. 99. Minn, A.J., et al., Genes that mediate breast cancer metastasis to lung. Nature, 2005. 436(7050): p. 518–524. 100. Lücke, J., et al., Protocol for generating lung and liver metastasis in mice using models that bypass intravasation. STAR Protoc, 2024. 5(1): p. 102696. 101. Dafflon, C., A. Santamaría-Martínez, and P. Ordóñez-Morán, An Intrasplenic Injection Model for the Study of Cancer Stem Cell Seeding Capacity. Methods Mol Biol, 2020. 2171: p. 293–302. 102. Geisler, J.A., et al., Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging. JoVE, 2020(160): p. e61272. 103. Zhang, Y., et al., Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation. Oncol Lett, 2018. 15(5): p. 6233–6240. 104. Bos, P.D., et al., Genes that mediate breast cancer metastasis to the brain. Nature, 2009. 459(7249): p. 1005–1009. 105. Zhang, C., F.J. Lowery, and D. Yu, Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis. J Vis Exp, 2017(120). 106. Chen, J.F., et al., An in vivo screen identifies NAT10 as a master regulator of brain metastasis. Science Advances, 2025. 11(13): p. eads6021. 107. Pan, J.-K., et al., MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer. Oncogene, 2021. 40(9): p. 1737–1751. 108. Wang, M., et al., Exosomal CD44 Transmits Lymph Node Metastatic Capacity Between Gastric Cancer Cells via YAP-CPT1A-Mediated FAO Reprogramming. Frontiers in Oncology, 2022. Volume 12 - 2022. 109. Zeng, F., et al., Fatty acid β-oxidation promotes breast cancer stemness and metastasis via the miRNA-328-3p-CPT1A pathway. Cancer Gene Therapy, 2022. 29(3): p. 383–395. 110. Zheng, J., Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett, 2012. 4(6): p. 1151–1157. 111. Kim, Y.-N., et al., Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis. International Journal of Cell Biology, 2012. 2012(1): p. 306879. 112. Hawk, M.A. and Z.T. Schafer, Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem, 2018. 293(20): p. 7531–7537. 113. Schafer, Z.T., et al., Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature, 2009. 461(7260): p. 109–13. 114. Parida, P.K., et al., Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases. Nature Cancer, 2023. 4(6): p. 893–907. 115. Abbott, K.L., et al., Nutrient requirements of organ-specific metastasis in breast cancer. Nature, 2026. 116. Li, T., et al., Metabolic reprogramming in bone metastasis of human cancers. Frontiers in Cell and Developmental Biology, 2025. Volume 13 - 2025. 117. Poswal, J. and C.C. Mandal, Lipid metabolism dysregulation for bone metastasis and its prevention. Expert Review of Anticancer Therapy, 2025. 25(6): p. 657–673. 118. Li, J., et al., The IGF2BP3–FASN axis drives lipid metabolic reprogramming to promote brain colonization in non-small cell lung cancer. Cell Death & Disease, 2025. 16(1): p. 684. 119. Zaidi, N., et al., Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. Progress in Lipid Research, 2013. 52(4): p. 585–589. 120. Yin, H., et al., Emerging Roles of Lipophagy in Cancer Metastasis. Cancers, 2022. 14(18): p. 4526. 121. Shang, C., J. Qiao, and H. Guo, The dynamic behavior of lipid droplets in the pre-metastatic niche. Cell Death & Disease, 2020. 11(11): p. 990. 122. Mouneimne, G., et al., Differential Remodeling of Actin Cytoskeleton Architecture by Profilin Isoforms Leads to Distinct Effects on Cell Migration and Invasion. Cancer Cell, 2012. 22(5): p. 615–630. 123. Schick, J. and E. Raz, Blebs—Formation, Regulation, Positioning, and Role in Amoeboid Cell Migration. Frontiers in Cell and Developmental Biology, 2022. Volume 10 - 2022. 124. Kilwein, M.D. and M.A. Welte, Lipid droplet motility and organelle contacts. Contact (Thousand Oaks), 2019. 2. 125. Clement, E., et al., Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. The EMBO Journal, 2020. 39(3): p. EMBJ2019102525. 126. Ma, C., et al., Lipotoxicity, lipid peroxidation and ferroptosis: a dilemma in cancer therapy. Cell Biol Toxicol, 2025. 41(1): p. 75. 127. Marschallinger, J., et al., Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nature Neuroscience, 2020. 23(2): p. 194–208. 128. Stubbs, C.D. and A.D. Smith, The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1984. 779(1): p. 89–137. 129. Taraboletti, G., et al., Membrane fluidity affects tumor-cell motility, invasion and lung-colonizing potential. Int J Cancer, 1989. 44(4): p. 707–13. 130. Nakazawa, I. and M. Iwaizumi, A correlation between cancer metastases and the fluidity of cancer cell membrane. Tohoku J Exp Med, 1982. 137(3): p. 325–8. 131. Chen, X., C. Guo, and J. Kong, Oxidative stress in neurodegenerative diseases. Neural Regen Res, 2012. 7(5): p. 376–85. 132. Zhang, Y., et al., NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. Nature Reviews Cardiology, 2020. 17(3): p. 170–194. 133. Zhang, P., et al., Oxidative stress and diabetes: antioxidative strategies. Frontiers of Medicine, 2020. 14(5): p. 583–600. 134. Fang, J., H.-S. Wong, and M.D. Brand, Production of superoxide and hydrogen peroxide in the mitochondrial matrix is dominated by site IQ of complex I in diverse cell lines. Redox Biology, 2020. 37: p. 101722. 135. Muller, F.L., Y. Liu, and H. Van Remmen, Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem, 2004. 279(47): p. 49064–73. 136. Xiao, J., et al., Fenton-Like Reaction: Recent Advances and New Trends. Chemistry – A European Journal, 2024. 30(24): p. e202304337. 137. Walker, C.L., et al., Redox Regulation of Homeostasis and Proteostasis in Peroxisomes. Physiological Reviews, 2017. 98(1): p. 89–115. 138. Zito, E., ERO1: A protein disulfide oxidase and H2O2 producer. Free Radical Biology and Medicine, 2015. 83: p. 299–304. 139. Walter, P. and D. Ron, The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation. Science, 2011. 334(6059): p. 1081–1086. 140. Booth, D.M., et al., Oxidative bursts of single mitochondria mediate retrograde signaling toward the ER. Mol Cell, 2021. 81(18): p. 3866–3876.e2. 141. Bubici, C., et al., Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene, 2006. 25(51): p. 6731–6748. 142. Lee, S.-R., et al., Reversible Inactivation of the Tumor Suppressor PTEN by H2O2*. Journal of Biological Chemistry, 2002. 277(23): p. 20336–20342. 143. Meng, T.-C., et al., Regulation of Insulin Signaling through Reversible Oxidation of the Protein-tyrosine Phosphatases TC45 and PTP1B*. Journal of Biological Chemistry, 2004. 279(36): p. 37716–37725. 144. Salmeen, A., et al., Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature, 2003. 423(6941): p. 769–773. 145. Son, Y., et al., Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways? Journal of Signal Transduction, 2011. 2011(1): p. 792639. 146. Seth, D. and J. Rudolph, Redox Regulation of MAP Kinase Phosphatase 3. Biochemistry, 2006. 45(28): p. 8476–8487. 147. Morgan, M.J. and Z.-g. Liu, Crosstalk of reactive oxygen species and NF-κB signaling. Cell Research, 2011. 21(1): p. 103–115. 148. Manuelli, V., et al., Regulation of redox signaling in HIF-1-dependent tumor angiogenesis. The FEBS Journal, 2022. 289(18): p. 5413–5425. 149. Redza-Dutordoir, M. and D.A. Averill-Bates, Activation of apoptosis signalling pathways by reactive oxygen species. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016. 1863(12): p. 2977–2992. 150. Su, L.-J., et al., Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis. Oxidative Medicine and Cellular Longevity, 2019. 2019(1): p. 5080843. 151. Dixon, Scott J., et al., Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell, 2012. 149(5): p. 1060–1072. 152. Chen, X., et al., Iron Metabolism in Ferroptosis. Frontiers in Cell and Developmental Biology, 2020. Volume 8 - 2020. 153. Yang, W.S., et al., Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proceedings of the National Academy of Sciences, 2016. 113(34): p. E4966–E4975. 154. Sun, D., et al., Lipid metabolism in ferroptosis: mechanistic insights and therapeutic potential. Frontiers in Immunology, 2025. 16. 155. Kagan, V.E., et al., Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature Chemical Biology, 2017. 13(1): p. 81–90. 156. Agmon, E., et al., Modeling the effects of lipid peroxidation during ferroptosis on membrane properties. Sci Rep, 2018. 8(1): p. 5155. 157. An, X., et al., Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death & Disease, 2024. 15(8): p. 556. 158. Lubos, E., J. Loscalzo, and D.E. Handy, Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal, 2011. 15(7): p. 1957–97. 159. Guo, X., et al., Characterization of recombinant human gastrointestinal glutathione peroxidase mutant produced in Escherichia coli. Free Radical Research, 2015. 49(3): p. 228–235. 160. Zhao, L., et al., Kidney Toxicity and Response of Selenium Containing Protein-glutathione Peroxidase (Gpx3) to CdTe QDs on Different Levels. Toxicological Sciences, 2019. 168(1): p. 201–208. 161. Taylor, A., et al., Epididymal specific, selenium-independent GPX5 protects cells from oxidative stress-induced lipid peroxidation and DNA mutation. Hum Reprod, 2013. 28(9): p. 2332–42. 162. Shema, R., et al., Synthetic lethal screening in the mammalian central nervous system identifies Gpx6 as a modulator of Huntington’s disease. Proceedings of the National Academy of Sciences, 2015. 112(1): p. 268–272. 163. Ramming, T. and C. Appenzeller-Herzog, Destroy and Exploit: Catalyzed Removal of Hydroperoxides from the Endoplasmic Reticulum. International Journal of Cell Biology, 2013. 2013(1): p. 180906. 164. Nguyen, V.D., et al., Two Endoplasmic Reticulum PDI Peroxidases Increase the Efficiency of the Use of Peroxide during Disulfide Bond Formation. Journal of Molecular Biology, 2011. 406(3): p. 503–515. 165. Ursini, F., et al., Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1982. 710(2): p. 197–211. 166. Arai, M., et al., Import into Mitochondria of Phospholipid Hydroperoxide Glutathione Peroxidase Requires a Leader Sequence. Biochemical and Biophysical Research Communications, 1996. 227(2): p. 433–439. 167. Puglisi, R., et al., The nuclear form of glutathione peroxidase 4 colocalizes and directly interacts with protamines in the nuclear matrix during mouse sperm chromatin assembly. Spermatogenesis, 2014. 4(1): p. e28460. 168. Maiorino, M., et al., Distinct Promoters Determine Alternative Transcription of gpx-4 into Phospholipid-Hydroperoxide Glutathione Peroxidase Variants*. Journal of Biological Chemistry, 2003. 278(36): p. 34286–34290. 169. Seibt, T.M., B. Proneth, and M. Conrad, Role of GPX4 in ferroptosis and its pharmacological implication. Free Radical Biology and Medicine, 2019. 133: p. 144–152. 170. Yang, Wan S., et al., Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell, 2014. 156(1): p. 317–331. 171. Imai, H., et al., Early embryonic lethality caused by targeted disruption of the mouse PHGPx gene. Biochem Biophys Res Commun, 2003. 305(2): p. 278–86. 172. Yant, L.J., et al., The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic Biol Med, 2003. 34(4): p. 496–502. 173. Imai, H., et al., Depletion of selenoprotein GPx4 in spermatocytes causes male infertility in mice. J Biol Chem, 2009. 284(47): p. 32522–32. 174. Imai, H., et al., Failure of the Expression of Phospholipid Hydroperoxide Glutathione Peroxidase in the Spermatozoa of Human Infertile Males1. Biology of Reproduction, 2001. 64(2): p. 674–683. 175. Roveri, A., et al., Cardiolipin drives the catalytic activity of GPX4 on membranes: Insights from the R152H mutant. Redox Biology, 2023. 64: p. 102806. 176. Seiler, A., et al., Glutathione Peroxidase 4 Senses and Translates Oxidative Stress into 12/15-Lipoxygenase Dependent- and AIF-Mediated Cell Death. Cell Metabolism, 2008. 8(3): p. 237–248. 177. Shen, Q., F.F. Chu, and P.E. Newburger, Sequences in the 3'-untranslated region of the human cellular glutathione peroxidase gene are necessary and sufficient for selenocysteine incorporation at the UGA codon. Journal of Biological Chemistry, 1993. 268(15): p. 11463–11469. 178. Ingold, I., et al., Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis. Cell, 2018. 172(3): p. 409–422.e21. 179. Tosatto, S.C.E., et al., The Catalytic Site of Glutathione Peroxidases. Antioxidants & Redox Signaling, 2008. 10(9): p. 1515–1526. 180. Viswanathan, V.S., et al., Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 2017. 547(7664): p. 453–457. 181. Hangauer, M.J., et al., Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature, 2017. 551(7679): p. 247–250. 182. Ni, J., et al., Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells. Biochemical and Biophysical Research Communications, 2021. 567: p. 154–160. 183. Yang, C., et al., Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging (Albany NY), 2021. 13(10): p. 13515–13534. 184. Wang, Q., et al., GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis, 2021. 12(5): p. 426. 185. Herrera-Abreu, M.T., et al., Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer. Nat Commun, 2024. 15(1): p. 9550. 186. Song, X., et al., Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib. Front Oncol, 2020. 10: p. 597434. 187. Ubellacker, J.M., et al., Lymph protects metastasizing melanoma cells from ferroptosis. Nature, 2020. 585(7823): p. 113–118. 188. Cheng, L., et al., SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4. Cell Death & Disease, 2023. 14(1): p. 74. 189. Li, D., et al., CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1. Oncogene, 2023. 42(2): p. 83–98. 190. Hu, C., et al., Inhibition of glutathione peroxidase 4 suppresses gastric cancer peritoneal metastasis via regulation of RCC2 homeostasis. Redox Biology, 2025. 80: p. 103519. 191. 黃鈺雯, 探討第二型人類表皮生長因子受體陽性癌症之抗藥性機制. 2022, 國立臺灣大學. 192. Li, Z., et al., HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. J Clin Invest, 2024. 134(7). 193. Mullenbach, G.T., et al., Sequence of a cDNA coding for human glutathione peroxidase confirms TGA encodes active site selenocysteine. Nucleic Acids Res, 1987. 15(13): p. 5484. 194. Mix, H., A.V. Lobanov, and V.N. Gladyshev, SECIS elements in the coding regions of selenoprotein transcripts are functional in higher eukaryotes. Nucleic Acids Res, 2007. 35(2): p. 414–23. 195. Endale, H.T., W. Tesfaye, and T.A. Mengstie, ROS induced lipid peroxidation and their role in ferroptosis. Frontiers in Cell and Developmental Biology, 2023. Volume 11 - 2023. 196. Heidersbach, A.J., et al., A versatile, high-efficiency platform for CRISPR-based gene activation. Nature Communications, 2023. 14(1): p. 902. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/102129 | - |
| dc.description.abstract | 乳癌腦轉移（Breast cancer brain metastasis, BCBM）是晚期乳癌患者發病率與死亡率的主要原因，其中以 HER2 陽性乳癌與三陰性乳癌患者的發生率更高。儘管全身性療法的進步能夠顯著延長患者的存活率，但血腦屏障（blood-brain barrier, BBB）會阻擋大多數全身性治療藥物的進入，使腦部成為癌細胞逃避藥物攻擊的「庇護所」，導致乳癌腦轉移的發生率上升。因此，深入了解乳癌腦轉移的分子機制並尋找潛在的治療靶點至關重要。
本研究分為兩個部分：第一個部分透過建立乳癌腦轉移小鼠模型及公開資料庫分析探討乳癌腦轉移之分子機制；第二部分則著重於抗氧化酶 GPX4 在乳癌腦轉移中的作用。 在本研究的第一部分中，我們成功建立乳癌腦轉移小鼠模型，並分離出具腦轉移與脊髓轉移潛力的轉移衍生細胞株。這些轉移衍生細胞展現出較高的遷移能力與惡性特徵，其中腦轉移衍生細胞更顯示出明確的腦轉移傾向。透過公開資料庫分析與棕櫚酸氧化壓力試驗，指出脂肪酸代謝會參與乳癌腦轉移的調控過程。進一步結合RNA 定序分析與藥理抑制遷移試驗，顯示腦轉移衍生細胞可能上調脂肪酸合成，以增強其遷移能力。綜上所述，本研究提出脂肪酸合成可能為乳癌腦轉移之驅動力，並能夠作為潛在的代謝治療靶點。 本研究第二部分探討癌細胞於轉移過程中面臨氧化壓力之調控機制，在轉移過程中，癌細胞內的活性氧（reactive oxygen species, ROS）水平會顯著升高。為了應對這種壓力並在轉移過程中存活，癌細胞會上調其抗氧化系統。GPX4是細胞內重要的抗氧化酶，能夠清除脂質過氧化物，抑制鐵死亡的發生。近年來多項研究指出，GPX4 不僅與乳癌治療抗藥性有關，更與腫瘤遠端轉移密切相關。 實驗室先前研究發現，對Trastuzumab具抗藥性的乳癌細胞相較其親代細胞，展現出更強的遷移能力，並伴隨GPX4表現的上調，暗示GPX4 與抗藥性乳癌細胞之轉移潛力提升相關。臨床上，對Trastuzumab 具抗藥性的乳癌患者常以腦部作為疾病復發的初始轉移部位。透過公開資料庫分析，發現BCBM樣本中 GPX4 表現量及其相關代謝途徑呈現上調趨勢，暗示 GPX4 可能參與乳癌腦轉移的調控過程。在功能性層面上，抑制 GPX4 會影響乳癌細胞的遷移行為。然而，受限於目前建立之GPX4過度表現系統，本研究未能更精確釐清 GPX4 在乳癌腦轉移中的實際調控角色。綜上所述，本研究指出GPX4可能在BCBM過程中扮演關鍵調控角色，而其促進 BCBM 發生的具體分子機制，將於討論部分進一步闡述與探討。 | zh_TW |
| dc.description.abstract | Breast cancer brain metastasis (BCBM) is a major cause of morbidity and mortality in breast cancer patients, particularly those with HER2-positive and triple-negative subtypes. Despite advancements in systemic therapies that significantly prolong patient survival, the incidence of BCBM has increased, largely because the blood-brain barrier (BBB) impedes the entry of most therapeutic drugs. Therefore, understanding the molecular mechanisms underlying BCBM is crucial for developing effective and novel therapeutic strategies.
This study is divided into two parts. The first part is to investigate the molecular mechanisms of BCBM through the establishment of a mouse model and public database analysis. The other is to investigate the role of GPX4 in BCBM. In the first part, we established a BCBM mouse model and isolated brain-metastasis and spinal-metastasis derived cells. These metastasis-derived cells enhanced migratory and aggressive characteristics, with brain metastasis-derived cells showing a distinct organotropism for the brain. Public database analysis revealed that fatty acid metabolism might be involved in breast cancer brain metastasis. Furthermore, integration of RNA sequencing with pharmacological migration inhibition assays demonstrated that brain metastasis-derived cells upregulated fatty acid synthesis to enhance their migratory ability. In conclusion, these findings suggest that fatty acid synthesis serves as a key metabolic driver of BCBM and represents a potential therapeutic target. For the second part of the thesis, during metastasis, cancer cells elevated intracellular reactive oxygen species (ROS), leading to oxidative stress. Consequently, cancer cells frequently upregulate their antioxidant systems to adapt oxidative stress, facilitating their survival and metastasis. GPX4 reduces lipid peroxides thereby inhibiting ferroptosis. Recent studies indicate that GPX4 plays a key role not only in therapeutic resistance in breast cancer but also in distant metastasis. Our previous work observed that Trastuzumab-resistant breast cancer cells exhibited enhanced migratory capacity and accompanied by increased GPX4 expression. Clinically, trastuzumab-resistant breast cancer patients frequently develop brain metastasis as an early site of disease relapse. Further analysis of public datasets revealed that GPX4 expression and GPX4-associated metabolic pathways were upregulated in BCBM samples. Functionally, suppression of GPX4 affected the migratory behavior of breast cancer cells. However, owing to limitations of current GPX4 overexpression system, the precise regulatory role of GPX4 in BCBM could not be fully elucidated in this study. In conclusion, this study suggests that GPX4 may play a key regulatory role in the development of breast cancer brain metastasis. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2026-03-13T16:39:59Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2026-03-13T16:39:59Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 誌謝 i
摘要 ii Abstract iv 縮寫表 vi 圖次 xiv 附錄圖次 xvii 章節一、透過小鼠模型建立和公開資料庫分析探討乳癌腦轉移之分子機制 1 第一章、前言 1 1.1 乳癌 1 1.1.1 乳癌分類與治療 1 1.2 乳癌與轉移 4 1.3 乳癌腦轉移與治療 5 1.4 癌細胞內的脂質代謝重編程 6 1.4.1 脂質攝取 (Lipid uptake) 7 1.4.2 脂質生合成 (Lipid synthesis) 8 內源性脂肪酸合成 9 內源性膽固醇合成 10 內源性磷脂質合成 10 1.4.3 脂滴生成 (Lipid droplet formation) 12 1.4.4 脂質降解代謝 (Lipid degradation) 13 1.4.4.1 脂解作用 (Lipolysis) 13 1.4.4.2 脂噬作用 (Lipophagy) 14 1.4.5 脂肪酸氧化 15 第二章、研究目的 18 第三章、研究材料與方法 19 3.1 乳癌腦轉移小鼠模型建立以及轉移細胞分離 19 腦轉移細胞分離 19 脊髓轉移細胞分離 20 3.2 細胞培養以及藥物使用 21 3.3 Transwell細胞遷移試驗 21 3.4 細胞增殖試驗 22 3.5 脂滴染色分析 22 3.6 脂肪酸氧化能力檢測 23 3.7 蛋白質萃取與定量 25 3.8蛋白質電泳及西方墨點法 25 3.9 RNA萃取 26 3.10 RNA定序（RNA sequencing, RNA-seq） 27 3.11 免疫螢光染色 (Immunofluorescence) 27 3.12 生物資訊分析 (Bioinformatic analysis) 28 3.13 統計分析 29 第四章、實驗結果 30 4.1 建立乳癌腦轉移小鼠模型並分離轉移衍生細胞株 30 4.2 乳癌轉移衍生細胞株展現更具侵襲性之形態與功能特徵 30 4.3 乳癌腦轉移衍生細胞株具腦轉移傾向性與分子特徵 31 4.4氧化磷酸化與不飽和脂肪酸生合成與乳癌腦轉移相關 32 4.5 乳癌腦轉移衍生細胞具增強之脂肪酸氧化能力 32 4.6 脂肪酸氧化並非乳癌腦轉移衍生細胞遷移能力提升之主要機制 33 4.7 乳癌腦轉移衍生細胞可能上調脂肪酸合成與/或脂噬作用 33 4.8脂肪酸合成為驅動乳癌腦轉移衍生細胞遷移能力提升之關鍵機制 35 4.9脂噬作用並非促進腦轉移衍生細胞遷移提升之主要機制 36 第五章、結論 37 第六章、討論 38 6.1 建立乳癌腦轉移小鼠模型及其腦轉移趨向性探討 38 6.2 脂肪酸氧化在乳癌腦轉移中的潛在調控角色 39 6.3脂肪酸合成途徑在不同轉移微環境中的差異調控角色 41 6.4脂肪酸合成調控乳癌腦轉移的可能機制 42 6.5細胞膜流動性提升可能為乳癌腦轉移之潛在促進機制 44 6.6 HER2陽型乳癌腦轉移小鼠模型建立與乳癌腦轉移潛在機制驗證 45 圖 46 附錄圖 66 章節二、探討抗氧化酶GPX4在乳癌腦轉移中的作用 69 第一章、前言 69 1.1 氧化壓力 69 1.1.1 ROS來源 69 1.1.2 ROS在癌細胞內的雙重作用 70 1.2 穀胱甘肽過氧化物酶家族 (Glutathione Peroxidase Family) 72 1.3 Glutathione Peroxidase Family 4 73 1.3.1 GPX4的介紹 73 1.3.2 GPX4活性 74 1.3.3 GPX4與治療抗藥性 75 1.3.4 GPX4與癌症轉移 76 1.4 實驗室過往研究 77 第二章、研究目的 78 第三章、研究材料與方法 79 3.1 細胞培養與藥物使用 79 3.2 Transwell細胞遷移試驗 79 3.3 酸性磷酸酶試驗 (Acid phosphatase test, ACP) 80 3.4 GPX4表達質體建構及製備 81 3.4.1 GPX4 ORF cDNA clone來源 81 3.4.2 pcDNA3.1-GPX4-myc-His 82 3.4.2 pCDH-GPX4-myc-His 82 3.5 RNAi基因敲低 84 3.5.1 shRNA穩定基因敲低 84 3.5.2 siRNA暫時性基因敲低（Transient knockdown） 85 3.6 慢病毒製作與轉導 85 3.7 蛋白質萃取與定量 (與章節一第三章3.7同) 86 3.8 西方墨點法 (與章節一第三章3.8同) 86 3.9 脂質過氧化物含量偵測 86 3.10 動物實驗 (Animal experiment) 87 3.11 生物資訊分析 (Bioinformatic analysis) 88 3.12 統計分析 89 第四章、實驗結果 90 4.1 抗藥性癌細胞具有較高的轉移潛力與 GPX4 表現 90 4.2 GPX4表現與抗藥性癌細胞之高轉移潛力以及乳癌患者較差的預後相關 90 4.3 乳癌腦轉移樣本具有較高的GPX4表達並上調與其相關之代謝途徑 91 4.4 GPX4會促進乳癌遷移能力 91 4.5 GPX4穩定過度表達細胞建立 93 4.6 GPX4 過度表現對乳癌細胞遷移與腦轉移能力無明顯影響 95 4.7 GPX4 過度表現細胞之酵素活性受損 95 第五章、結論 97 第六章、討論 98 6.1 GPX4過表達之活性評估與其乳癌細胞遷移能力的影響驗證 98 6.2 建立體外血腦屏障模型以探討GPX4在乳癌腦轉移中的作用 98 6.3 透過體內小鼠實驗直接驗證GPX4促進乳癌腦轉移的作用 99 6.4 GPX4在乳癌腦轉移中可能的調控作用 100 圖 101 附錄圖 120 參考文獻 122 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 乳癌腦轉移 | - |
| dc.subject | 脂質代謝重編程 | - |
| dc.subject | 氧化壓力 | - |
| dc.subject | 穀胱甘肽過氧化物酶4 | - |
| dc.subject | breast cancer brain metastasis | - |
| dc.subject | lipid metabolism reprogramming | - |
| dc.subject | oxidative stress | - |
| dc.subject | GPX4 | - |
| dc.title | 結合公開資料庫分析與小鼠模型建立以探討乳癌腦轉移之分子機制 | zh_TW |
| dc.title | Investigating the molecular mechanisms of breast cancer brain metastasis through public database analysis and mouse model establishment | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 114-1 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 楊雅倩;蘇剛毅;林能裕;卓爾婕 | zh_TW |
| dc.contributor.oralexamcommittee | Ya-Chien Yang;Kang-Yi Su;Neng-Yu Lin;Er-Chieh Cho | en |
| dc.subject.keyword | 乳癌腦轉移,脂質代謝重編程氧化壓力穀胱甘肽過氧化物酶4 | zh_TW |
| dc.subject.keyword | breast cancer brain metastasis,lipid metabolism reprogrammingoxidative stressGPX4 | en |
| dc.relation.page | 142 | - |
| dc.identifier.doi | 10.6342/NTU202600653 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2026-02-03 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 醫學檢驗暨生物技術學系 | - |
| dc.date.embargo-lift | N/A | - |
| 顯示於系所單位： | 醫學檢驗暨生物技術學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-114-1.pdf 未授權公開取用 | 7.48 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。